OMER Quote, Financials, Valuation and Earnings

Gilead Sciences, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of 27.55%. Omeros Corp.'s return on equity of -- beat Gilead Sciences, Inc.'s return on equity of 41.72%.

Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 215.62%. On the other hand Gilead Sciences, Inc. has an analysts' consensus of $155.41 which suggests that it could grow by 2.65%. Given that Omeros Corp. has higher upside potential than Gilead Sciences, Inc., analysts believe Omeros Corp. is more attractive than Gilead Sciences, Inc..

Omeros Corp. has a beta of 2.446, which suggesting that the stock is 144.588% more volatile than S&P 500. In comparison Gilead Sciences, Inc. has a beta of 0.360, suggesting its less volatile than the S&P 500 by 63.985%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Gilead Sciences, Inc. offers a yield of 2.09% to investors and pays a quarterly dividend of $0.79 per share. Omeros Corp. pays -- of its earnings as a dividend. Gilead Sciences, Inc. pays out 46.61% of its earnings as a dividend. Gilead Sciences, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omeros Corp. quarterly revenues are --, which are smaller than Gilead Sciences, Inc. quarterly revenues of $7.9B. Omeros Corp.'s net income of -$21.2M is lower than Gilead Sciences, Inc.'s net income of $2.2B. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Gilead Sciences, Inc.'s PE ratio is 22.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 6.46x for Gilead Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Merck & Co., Inc. has a net margin of -- compared to Omeros Corp.'s net margin of 18.06%. Omeros Corp.'s return on equity of -- beat Merck & Co., Inc.'s return on equity of 39.63%.

Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 215.62%. On the other hand Merck & Co., Inc. has an analysts' consensus of $126.00 which suggests that it could grow by 3.06%. Given that Omeros Corp. has higher upside potential than Merck & Co., Inc., analysts believe Omeros Corp. is more attractive than Merck & Co., Inc..

Omeros Corp. has a beta of 2.446, which suggesting that the stock is 144.588% more volatile than S&P 500. In comparison Merck & Co., Inc. has a beta of 0.280, suggesting its less volatile than the S&P 500 by 72.042%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & Co., Inc. offers a yield of 2.68% to investors and pays a quarterly dividend of $0.85 per share. Omeros Corp. pays -- of its earnings as a dividend. Merck & Co., Inc. pays out 45.05% of its earnings as a dividend. Merck & Co., Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Omeros Corp. quarterly revenues are --, which are smaller than Merck & Co., Inc. quarterly revenues of $16.4B. Omeros Corp.'s net income of -$21.2M is lower than Merck & Co., Inc.'s net income of $3B. Notably, Omeros Corp.'s price-to-earnings ratio is -- while Merck & Co., Inc.'s PE ratio is 16.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 4.72x for Merck & Co., Inc.. Usually stocks with elevated PS ratios are considered overvalued.

REGENXBIO, Inc. has a net margin of -- compared to Omeros Corp.'s net margin of -208.32%. Omeros Corp.'s return on equity of -- beat REGENXBIO, Inc.'s return on equity of -73.5%.

Omeros Corp. has a consensus price target of $38.00, signalling upside risk potential of 215.62%. On the other hand REGENXBIO, Inc. has an analysts' consensus of $29.18 which suggests that it could grow by 258.5%. Given that REGENXBIO, Inc. has higher upside potential than Omeros Corp., analysts believe REGENXBIO, Inc. is more attractive than Omeros Corp..

Omeros Corp. has a beta of 2.446, which suggesting that the stock is 144.588% more volatile than S&P 500. In comparison REGENXBIO, Inc. has a beta of 1.052, suggesting its more volatile than the S&P 500 by 5.23%.

Omeros Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. REGENXBIO, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Omeros Corp. pays -- of its earnings as a dividend. REGENXBIO, Inc. pays out -- of its earnings as a dividend.

Omeros Corp. quarterly revenues are --, which are smaller than REGENXBIO, Inc. quarterly revenues of $29.7M. Omeros Corp.'s net income of -$21.2M is higher than REGENXBIO, Inc.'s net income of -$61.9M. Notably, Omeros Corp.'s price-to-earnings ratio is -- while REGENXBIO, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Omeros Corp. is -- versus 2.58x for REGENXBIO, Inc.. Usually stocks with elevated PS ratios are considered overvalued.